泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

已收盘 05-12 16:08:12

27.300

+0.600

+2.25%

最高27.350	最低26.350	成交量174.69万
今开26.850	昨收26.700	日振幅3.75%
总市值236.15亿	流通市值33.58亿	总股本8.65亿
成交额4,695万	换手率1.42%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":27.3,"timestamp":1747037292029,"preClose":26.7,"halted":0,"volume":1746885,"delay":0,"floatShares":123000000,"shares":865000000,"eps":0.5075815227979396,"marketStatus":"已收盘","change":0.6,"latestTime":"05-12 16:08:12","open":26.85,"high":27.35,"low":26.35,"amount":46947544,"amplitude":0.037453,"askPrice":27.3,"askSize":15400,"bidPrice":27.2,"bidSize":24700,"shortable":3,"etf":0,"ttmEps":0.4203490410916204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747099800000},"marketStatusCode":5,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":26.7,"dividendRate":0.022711,"openAndCloseTimeList":[[1747013400000,1747022400000],[1747026000000,1747036800000]],"volumeRatio":1.358151,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":44.65,"timestamp":1747033200000,"preClose":44.79,"halted":0,"volume":10065000,"delay":0,"premium":"-43.45"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2534213941","title":"荣昌生物(688331.SH)：抗体偶联药物RC278获得药物临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534213941","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534213941?lang=zh_cn&edition=full","pubTime":"2025-05-12 15:51","pubTimestamp":1747036312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(688331.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，新型抗体偶联(ADC)药物注射用RC278的临床试验申请获得受理。RC278是由荣昌生物自主研发的一款具有First-in-Class/Best-in-Class潜质的ADC分子，该分子能特异识别一个新型肿瘤靶点，并具有创新的连接子—毒素系统，在临床前研究中展现出广谱抗肿瘤活性、良好的安全性和药代动力学特征，将为晚期实体瘤患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1064131003.USD","BK1141","BK1576","09995","BK1574","LU1064130708.USD","LU2148510915.USD","LU1969619763.USD","03347","LU2328871848.SGD","BK0239","BK1161","688331"],"gpt_icon":0},{"id":"2534321815","title":"荣昌生物：抗体偶联药物RC278临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2534321815","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534321815?lang=zh_cn&edition=full","pubTime":"2025-05-12 15:40","pubTimestamp":1747035646,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2328871848.SGD","LU1969619763.USD","BK4080","LU2148510915.USD","BK4231","LU1064130708.USD","03347","BK0239","BK1583","LU1064131003.USD","BK1141","688331","BK1576","BK1161","BK1574","09995","ADC"],"gpt_icon":0},{"id":"2534619297","title":"百诚医药：BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征患者日间过度思睡治疗的临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2534619297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534619297?lang=zh_cn&edition=full","pubTime":"2025-05-12 15:07","pubTimestamp":1747033642,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051200013839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1583","BK0216","03347","301096","BK1576"],"gpt_icon":0},{"id":"1181990888","title":"港股异动 | 生物医药股持续回调，特朗普拟将药价立即降低30%-80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181990888","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181990888?lang=zh_cn&edition=full","pubTime":"2025-05-12 10:11","pubTimestamp":1747015870,"startTime":"0","endTime":"0","summary":"本周一（5月12日）港股盘初，生物医药股大幅回调，截至发稿 $歌礼制药-B(01672)$ 跌超10%， $康方生物(09926)$ 、 $再鼎医药(09688)$ 均跌超6%：消息面上，美国总统特朗普称，将在白宫签署行政命令。处方药和药品价格几乎将立即降低30%至80%，美国将以全球最低价格国家的价格购买药品。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","02269","02359","03347","06622","09995","00241","06606","03759","06185","603259","01801","06160","06996","06127","06618","WX"],"gpt_icon":0},{"id":"2534459027","title":"每周股票复盘：中恒集团（600252）回购进展与三芪颗粒临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2534459027","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534459027?lang=zh_cn&edition=full","pubTime":"2025-05-10 02:06","pubTimestamp":1746813977,"startTime":"0","endTime":"0","summary":"截至2025年5月9日收盘，中恒集团报收于2.47元，较上周的2.43元上涨1.65%。本周，中恒集团5月8日盘中最高价报2.51元。5月6日盘中最低价报2.42元。中恒集团当前最新总市值81.84亿元，在中药板块市值排名28/69，在两市A股市值排名1884/5145。基于《中药注册管理专门规定》中“三结合”的审评证据体系，获批豁免Ⅰ期临床试验。三芪颗粒获得药物临床试验批准有望为中恒集团进入市场广阔的慢性肾病领域奠定基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051000001492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600252","BK0012","BK1141","BK0028","BK0015","BK0188","03347","BK1576","BK1583","BK0239","BK0077"],"gpt_icon":0},{"id":"2534745587","title":"每周股票复盘：恒瑞医药（600276）多个药物获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534745587","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534745587?lang=zh_cn&edition=full","pubTime":"2025-05-10 01:03","pubTimestamp":1746810198,"startTime":"0","endTime":"0","summary":"截至2025年5月9日收盘，恒瑞医药报收于52.81元，较上周的51.1元上涨3.35%。根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051000001141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","LU2488822045.USD","BK0060","LU1969619763.USD","600276","03347","LU2148510915.USD","LU1064131003.USD","BK0012","LU2328871848.SGD","BK1583","BK0183","BK1576","BK0188","LU1328615791.USD","BK1141","LU0405327148.USD","LU0405327494.USD","LU1064130708.USD","BK0028"],"gpt_icon":0},{"id":"2534348178","title":"广生堂：GST-HG131联合GST-HG141的II期临床试验申请已获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534348178","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534348178?lang=zh_cn&edition=full","pubTime":"2025-05-09 20:52","pubTimestamp":1746795153,"startTime":"0","endTime":"0","summary":"GST-HG131为表面抗原抑制剂，GST-HG141为核衣壳调节剂，二者都是广生堂乙肝登峰计划的重要组成部分。基于GST-HG131和GST-HG141的临床前研究和已披露的临床研究结果，GST-HG131对HBsAg具有明显抑制作用，GST-HG141片对HBV DNA有显著的抑制效应且明显降低pgRNA，间接体现了对HBV cccDNA 的潜在有效抑制和耗竭作用，两者在抗病毒机制上预计协同互补。GST-HG131 联合 GST-HG141 的 II 期临床试验申请已获得批准，旨在探索基于核苷（酸）类似物基础治疗上，GST-HG131片联合GST-HG141片，三联全口服用药挑战乙肝临床治愈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900037830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","03347","BK1576","300436","BK0239","BK1141"],"gpt_icon":0},{"id":"2534483441","title":"智飞生物(300122.SZ)：四价流感病毒裂解疫苗(ZFA02佐剂)进入Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534483441","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534483441?lang=zh_cn&edition=full","pubTime":"2025-05-09 19:48","pubTimestamp":1746791327,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)研发的四价流感病毒裂解疫苗(ZFA02佐剂)(简称“佐剂四价流感疫苗”)在河北省开展Ⅰ/Ⅱ期临床试验。智飞龙科马自主研发的佐剂四价流感疫苗，含公司自主研制的ZFA02佐剂，接种后可刺激机体产生针对流感病毒抗原血凝素(HA)体液免疫和细胞免疫反应，用于预防疫苗相关型别的流感病毒引起的流行性感冒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","LU1064131003.USD","LU2148510915.USD","BK0239","BK0046","BK0196","BK0188","BK1576","LU2580892789.USD","BK0077","LU2580892862.HKD","LU1064130708.USD","LU1328615791.USD","03347","BK1583","300122","BK1141"],"gpt_icon":0},{"id":"2534488425","title":"智飞生物：佐剂四价流感疫苗进入Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534488425","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534488425?lang=zh_cn&edition=full","pubTime":"2025-05-09 19:41","pubTimestamp":1746790888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03347","LU1328615791.USD","BK1141","300122","BK0188","BK0239","LU1064130708.USD","LU2148510915.USD","BK1576","BK0046","BK1583","159646","LU2580892789.USD","LU2580892862.HKD","BK0196","LU1064131003.USD","BK0077"],"gpt_icon":0},{"id":"2534729488","title":"智飞生物最新公告：四价流感病毒裂解疫苗（ZFA02佐剂）进入Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534729488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534729488?lang=zh_cn&edition=full","pubTime":"2025-05-09 19:39","pubTimestamp":1746790774,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞龙科马研发的四价流感病毒裂解疫苗（ZFA02佐剂）在河北省开展Ⅰ/Ⅱ期临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900034769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","BK0046","LU2580892862.HKD","LU1064130708.USD","300122","03347","BK0239","BK0196","159646","BK1583","LU1064131003.USD","BK1141","BK1576","BK0188","BK0077","LU2580892789.USD"],"gpt_icon":0},{"id":"2534710069","title":"乐普医疗最新公告：子公司MWN109片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534710069","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534710069?lang=zh_cn&edition=full","pubTime":"2025-05-09 19:20","pubTimestamp":1746789657,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，由民为生物申报的MWN109片临床试验申请获得批准。MWN109片是乐普医疗自主研发的GLP-1/GIP/GCG活性脂肪酸链修饰多肽药物的口服剂型，适应症包括2型糖尿病和超重或肥胖。不过，该在研项目尚处于研发早期阶段，存在结果不确定性高、研发投入大、临床试验周期长等特点，以及临床试验失败、审评审批失败和竞争加剧等风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900033831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK1141","300003","BK1583","BK0114","BK0201","BK0042","BK0028","BK0251","BK1576","BK0113","03347"],"gpt_icon":0},{"id":"2534100774","title":"石药集团1类新药SYH2046获FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534100774","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534100774?lang=zh_cn&edition=full","pubTime":"2025-05-09 19:01","pubTimestamp":1746788515,"startTime":"0","endTime":"0","summary":"5月9日，石药集团发布公告，宣布其开发的化药1类新药SYH2046片已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品也已于2025年4月获得中国国家药品监督管理局的批准，允许在中国进行临床试验。SYH2046片是一款具有完全自主知识产权的全新结构first-in-class小分子药物，主要适应症为急性心肌梗死后心力衰竭。目前，公司已在国内外提交多项该产品的专利申请。文章来源：财中社石药集团1类新药SYH2046获FDA批准开展临床试验","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0501845795.SGD","BK1141","LU1226287792.SGD","LU0072913022.USD","BK1583","IE0008368742.USD","BK1191","LU1226288253.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU0067412154.USD","LU1152091754.HKD","LU0326950275.SGD","LU1951186391.HKD","LU1993786604.SGD","LU1960683339.HKD","LU1152091168.USD","LU1226287529.USD","01093","IE00BZ08YS42.EUR","LU1226288170.HKD","IE00BZ08YR35.GBP","03347","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1807302812.USD","BK1576","SG9999004220.SGD","BK1521","IE00B031HY20.USD","LU1008478684.HKD","IE0008369823.USD","BK1515","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2534104693","title":"复星医药(02196)附属菌济健康获美国 FDA 药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534104693","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534104693?lang=zh_cn&edition=full","pubTime":"2025-05-09 18:48","pubTimestamp":1746787704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司上海菌济健康科技有限公司(以下简称“菌济健康”)收到美国 FDA(即美国食品药品监督管理局)关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开展 LBP-ShC4 的 I 期临床试验。LBP-ShC4 为集团自主研发的活体生物治疗产品，拟用于治疗雄激素脱发(AGA)。截至 2025 年 4 月，集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","BK0175","BK0060","600196","BK0096","BK0239","BK0187","BK0183","BK0196","BK0028","BK1593","02196","BK1515","BK1583","BK0012","BK1576","BK1141","BK1191"],"gpt_icon":0},{"id":"2534177637","title":"恒瑞医药(600276.SH)：SHR-1316(sc)注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534177637?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:55","pubTimestamp":1746784534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。具体为SHR-1316(sc)联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌中的药代动力学、安全性、耐受性及疗效的开放、多中心Ⅰ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","BK0060","BK0012","BK0188","LU1328615791.USD","BK1583","LU2328871848.SGD","BK1576","LU1064130708.USD","600276","BK0028","LU1064131003.USD","LU2488822045.USD","BK1141","03347","BK0183","BK0239","BK0196","LU1969619763.USD","LU0405327148.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2534775121","title":"恒瑞医药最新公告：子公司收到7项药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534775121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534775121?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:50","pubTimestamp":1746784257,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276.SH)公告称，子公司上海盛迪医药、苏州盛迪亚生物医药、上海恒瑞医药收到国家药监局核准签发的7项药物临床试验批准通知书，包括阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、注射用SHR-1826、注射用SHR-A1904、注射用SHR-A2009和注射用SHR-A2102，同意开展相关药物的临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900028438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","LU1328615791.USD","LU1969619763.USD","LU0405327148.USD","BK1576","LU2328871848.SGD","BK0196","BK1141","LU1064131003.USD","BK1583","BK0028","BK0239","600276","BK0183","LU1064130708.USD","LU2148510915.USD","BK0060","LU0405327494.USD","LU2488822045.USD","03347"],"gpt_icon":0},{"id":"2534554177","title":"恒瑞医药最新公告：子公司收到SHR-1316(sc)注射液临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534554177","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534554177?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:50","pubTimestamp":1746784229,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276.SH)公告称，公司收到国家药监局核准签发关于SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的人源化抗PD-L1单克隆抗体皮下制剂，拟用于广泛期小细胞肺癌的一线治疗。截至目前，相关项目累计研发投入约8.15亿元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900028439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2148510915.USD","BK0239","BK0012","LU2328871848.SGD","BK0028","BK0183","BK0196","BK1141","LU1064130708.USD","LU1969619763.USD","BK1576","600276","LU0405327148.USD","03347","LU1328615791.USD","LU1064131003.USD","BK0060","LU2488822045.USD","BK1583","LU0405327494.USD"],"gpt_icon":0},{"id":"2534766179","title":"复星医药最新公告：控股子公司菌济健康获美国FDA药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534766179","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534766179?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:23","pubTimestamp":1746782598,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海菌济健康科技有限公司（简称“菌济健康”）收到美国FDA（即美国食品药品监督管理局）关于同意LBP-ShC4开展临床试验的批准。菌济健康拟于条件具备后开展LBP-ShC4的I期临床试验。截至本公告日期（2025年5月9日），于全球范围内尚无用于治疗雄激素脱发（AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900027431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0196","BK1576","BK1593","BK1191","BK0060","BK0175","600196","BK1141","BK0096","BK1583","BK0188","BK1515","BK0028","BK0239","02196","BK0187","BK0183","03347"],"gpt_icon":0},{"id":"2534173533","title":"复星医药子公司获美国FDA批准开展AGA治疗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173533","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534173533?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:37","pubTimestamp":1746779855,"startTime":"0","endTime":"0","summary":"5月9日，复星医药发布公告，控股子公司菌济健康获得美国FDA关于LBP-ShC4开展临床试验的批准。公告指出，目前全球尚无用于治疗雄激素脱发的活体生物治疗产品获批上市。尽管获得临床试验批准，但药品研发存在风险，后续的临床研究仍需获得美国药品审评部门的审批，且临床试验可能因安全性和有效性问题而终止。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1576","BK1583","02196","BK1593","03347","BK1141","BK1515"],"gpt_icon":0},{"id":"2534210633","title":"每日卖空追踪 | 泰格医药 05月09日卖空量成交4.89万股，卖空比例为6.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534210633","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534210633?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:30","pubTimestamp":1746779431,"startTime":"0","endTime":"0","summary":"泰格医药北京时间05月09日，跌1.29%，卖空量成交4.89万股%，较上一交易日减少73.39%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509181413a6d8f125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509181413a6d8f125&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1583","BK1141","BK1576"],"gpt_icon":0},{"id":"2534120770","title":"复星医药(600196.SH)控股子公司获美国FDA药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534120770","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534120770?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:29","pubTimestamp":1746779394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司上海菌济健康科技有限公司(简称“菌济健康”)收到美国FDA(即美国食品药品监督管理局)关于同意LBP-ShC4开展临床试验的批准。菌济健康拟于条件具备后开展LBP-ShC4的I期临床试验。据悉，LBP-ShC4为集团(即公司及控股子公司/单位，下同)自主研发的活体生物治疗产品，拟用于治疗雄激素脱发(AGA)。截至本公告日期(2025年5月9日)，于全球范围内尚无用于治疗雄激素脱发(AGA)的活体生物治疗产品(包括单药或联合治疗方案)获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0196","BK1576","BK1593","BK1191","BK0060","BK0175","600196","BK1141","BK0096","BK1583","BK0188","BK1515","BK0028","BK0239","02196","BK0187","BK0183","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0595},{"period":"3month","weight":-0.0934},{"period":"6month","weight":-0.2946},{"period":"1year","weight":-0.2369},{"period":"ytd","weight":-0.1331}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.0821},{"period":"6month","weight":0.1032},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.14}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.098232},{"month":2,"riseRate":0.6,"avgChangeRate":0.033576},{"month":3,"riseRate":0.6,"avgChangeRate":-0.015339},{"month":4,"riseRate":0.2,"avgChangeRate":-0.055131},{"month":5,"riseRate":0.2,"avgChangeRate":-0.020065},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.033557}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}